5 research outputs found
A Novel Synthetic Smoothened Antagonist Transiently Inhibits Pancreatic Adenocarcinoma Xenografts in a Mouse Model
Hedgehog (Hh) signaling is over-activated in several solid tumors where it plays a central role in cell growth, stroma recruitment and tumor progression. In the Hh signaling pathway, the Smoothened (SMO) receptor comprises a primary drug target with experimental small molecule SMO antagonists currently being evaluated in clinical trials.Using Shh-Light II (Shh-L2) and alkaline phosphatase (AP) based screening formats on a "focused diversity" library we identified a novel small molecule inhibitor of the Hh pathway, MS-0022 (2-bromo-N-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)benzamide). MS-0022 showed effective Hh signaling pathway inhibition at the level of SMO in the low nM range, and Hh pathway inhibition downstream of Suppressor of fused (SUFU) in the low µM range. MS-0022 reduced growth in the tumor cell lines PANC-1, SUIT-2, PC-3 and FEMX in vitro. MS-0022 treatment led to a transient delay of tumor growth that correlated with a reduction of stromal Gli1 levels in SUIT-2 xenografts in vivo.We document the in vitro and in vivo efficacy and bioavailability of a novel small molecule SMO antagonist, MS-0022. Although MS-0022 primarily interferes with Hh signaling at the level of SMO, it also has a downstream inhibitory effect and leads to a stronger reduction of growth in several tumor cell lines when compared to related SMO antagonists
Parallel Liquid-Phase Synthesis of N-Substituted 6-Aminosulfonyl-2-oxo-1,2-dihydroquinoline-4-carboxamide and 6-Aminosulfonylquinoline-4-carboxamide Derivatives
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118):a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy
The
nuclear protein polyÂ(ADP-ribose) polymerase-1 (PARP-1) has a well-established
role in the signaling and repair of DNA and is a prominent target
in oncology, as testified by the number of candidates in clinical
testing that unselectively target both PARP-1 and its closest isoform
PARP-2. The goal of our program was to find a PARP-1 selective inhibitor
that would potentially mitigate toxicities arising from cross-inhibition
of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical
Sciences (NMS) chemical collection, followed by SAR optimization,
allowed us to discover 2-[1-(4,4-difluorocyclohexyl)Âpiperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118, <b>20by</b>).
NMS-P118 proved to be a potent, orally available, and highly selective
PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles
and high efficacy in vivo both as a single agent and in combination
with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively.
Cocrystal structures of <b>20by</b> with both PARP-1 and PARP-2
catalytic domain proteins allowed rationalization of the observed
selectivity
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
The systemic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to systemic therapy, bile acid release during a meal selectively activates intestinal FXR. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver. However, unlike systemic agonism, we find that Fex reduces diet-induced weight gain, body-wide inflammation and hepatic glucose production, while enhancing thermogenesis and browning of white adipose tissue (WAT). These pronounced metabolic improvements suggest tissue-restricted FXR activation as a new approach in the treatment of obesity and metabolic syndrome